Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach We read with interest the recent comments of Steinbach and Debatin 1 concerning the definition of 'sensitivity' with regard to minimal residual disease (MRD). What is usually meant by 'sensitivity' may be described more accurately as the estimated lower limit of detection of MRD. Although Steinbach and Debatin 1 write from the perspective of acute leukaemia, our experience is in the monitoring of chronic myeloid leukaemia. Recognizing important differences in the biology and treatment of acute and chronic leukaemia, there remain certain common principles of MRD monitoring that we wish to address. In particular, we emphasize that the limit of detection of MRD is dependent on (1) the performance characteristics of the analytical system and (2) the quality of the individual sample analysed.
Steinbach and Debatin 1 suggest that the term 'sensitivity' should be reserved to describe test sensitivity (number of test positives divided by true positives), but this definition may be impractical. First, sensitivity can be calculated only if the number of true positives (true test positives þ false negatives) is known. In acute leukaemia, the 'gold standard' indicator of the presence of MRD is relapse, and this can only be determined in retrospect. The estimation of test sensitivity using serial dilutions of cell lines with known cell numbers is possible, but this estimate of sensitivity may not be accurate when applied to patient samples. For instance, in the setting of chronic myeloid leukaemia MRD, the widely used K562 cell line has multiple copies of the BCR-ABL gene in each cell 2 and expresses high levels of BCR-ABL mRNA. The choice of cell line for the determination of sensitivity will influence the result, 3 and the use of cell lines to define sensitivity may overestimate the lower limit of detection (or underestimate the MRD burden) when extrapolated to patient samples.
It has earlier been reported that an optimized quantitative PCR assay can detect a single intact copy of the target sequence if the target sequence is present. 4 In an MRD setting, the number of target copies is low. As the limit of detection is approached, stochastic effects become important. For example, if 1 mg DNA were to contain on average one copy of the leukaemic sequence (estimated MRD level 6 Â 10 -6 ), then the probability that MRD would be detected if 1 mg DNA were analysed is only 63%, according to Poisson statistics. To have 95% confidence that the true level of MRD is o6 Â 10 -6 , it would be necessary to perform the assay at least three times, using X3 mg DNA. In quantitative assays, there is an increase in imprecision at very low levels of MRD, whereas in qualitative assays discrepant results will be seen in replicate analyses performed on the same sample.
3, 4 The number of replicate analyses performed, and the total amount of sample analysed, are critical determinants of the lower limit of detection achieved in any assay system. The estimated lower limit of detection of an assay should therefore include an indication of the amount of material used (for example, mg amount of DNA or RNA) and the number of replicate analyses.
In the field of chronic myeloid leukaemia, the potential to extend the detection limit of MRD by multiple replicate analyses was demonstrated by the identification of rare BCR-ABL transcripts in the blood of some normal individuals. 5 In a diagnostic laboratory processing large numbers of clinical samples, the risk of cross-contamination between patients expressing the same leukaemic mRNA transcript might preclude the use of such extremely sensitive PCR methods. Using genomic DNA PCR, on the other hand, there may be considerable interpatient diversity in the sequence of the MRD target (for example, immunoglobulin gene variable regions). In this setting, an MRD assay will be less susceptible to crosscontamination and it might be practical to use 30-40 replicates to increase sensitivity by 10-fold.
It is self-evident that the optimization of an assay system is irrelevant if the actual sample analysed is highly degraded. The problem of degradation of mRNA is well recognized, 6 but DNA may also be subject to degradation. 7 In addition, endogenous and exogenous substances (for example, heparin) in patient samples may be inhibitory to PCR. Therefore, an accurate estimation of the lower limit of detection of MRD by PCR methods should include a measurement of the amount of intact, amplifiable nucleic acid. In the monitoring of chronic myeloid leukaemia by quantitative real-time reverse transcriptase PCR, the control genes BCR, ABL and GUSB are commonly quantified in cDNA in parallel with the target BCR-ABL sequence to give an indication both of sample quality and of reverse transcription efficiency. 8 In genomic DNA, a control sequence could be selected on the basis that its sequence and copy number are not altered in leukaemic cells. The quantification of a control gene provides invaluable information about sample quality and should ensure that the level of MRD is not underestimated due to the use of sub-optimal samples.
In summary, the standardized reporting of the estimated lower limit of detection of PCR assays for leukaemia MRD is highly desirable, but should take into account (1) the amount of DNA or RNA in each assay and the number of replicates performed; and (2) the quality of the individual patient sample analysed. Glucocorticoid(GC)-induced apoptosis is an essential component in the treatment of lymphoid malignancies, most notably childhood acute lymphoblastic leukemia (ALL). Determining the extent of GC sensitivity/resistance has considerable clinical implications as it might be a relevant parameter in possible future patient-and tumor-adapted therapy regimens directed towards reducing the serious side effects of GC long-term
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